- Home
- APT vs MGNX Comparison
APT vs MGNX Comparison
Compare APT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APT
- MGNX
- Stock Information
- Founded
- APT 1983
- MGNX 2000
- Country
- APT Canada
- MGNX United States
- Employees
- APT N/A
- MGNX N/A
- Industry
- APT
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- APT
- MGNX Health Care
- Exchange
- APT Nasdaq
- MGNX Nasdaq
- Market Cap
- APT 61.6M
- MGNX 70.3M
- IPO Year
- APT 1995
- MGNX 2013
- Fundamental
- Price
- APT $4.50
- MGNX $1.55
- Analyst Decision
- APT
- MGNX Hold
- Analyst Count
- APT 0
- MGNX 9
- Target Price
- APT N/A
- MGNX $5.67
- AVG Volume (30 Days)
- APT 11.0K
- MGNX 594.5K
- Earning Date
- APT 05-08-2025
- MGNX 05-13-2025
- Dividend Yield
- APT N/A
- MGNX N/A
- EPS Growth
- APT 2.28
- MGNX N/A
- EPS
- APT 0.36
- MGNX N/A
- Revenue
- APT $58,180,000.00
- MGNX $154,050,000.00
- Revenue This Year
- APT N/A
- MGNX N/A
- Revenue Next Year
- APT N/A
- MGNX $80.86
- P/E Ratio
- APT $12.70
- MGNX N/A
- Revenue Growth
- APT N/A
- MGNX 255.31
- 52 Week Low
- APT $4.06
- MGNX $0.99
- 52 Week High
- APT $6.44
- MGNX $14.91
- Technical
- Relative Strength Index (RSI)
- APT 48.53
- MGNX 48.93
- Support Level
- APT $4.45
- MGNX $1.42
- Resistance Level
- APT $4.72
- MGNX $1.82
- Average True Range (ATR)
- APT 0.14
- MGNX 0.13
- MACD
- APT 0.04
- MGNX 0.01
- Stochastic Oscillator
- APT 47.62
- MGNX 32.91
About APT Alpha Pro Tech Ltd.
Alpha Pro Tech Ltd is involved in the business of developing, manufacturing, and marketing of disposable protective apparel, building supply, and infection control products principally in the United States. It operates its business through segment which includes Building Supply and Disposable Protective Apparel. It mainly offers a line of construction supply weatherization products, namely house wrap and synthetic roof underlayment as well as other woven material, different styles of disposable products like shoe covers, bouffant caps, gowns, coveralls, lab coats, frocks and other miscellaneous products. It also provides face masks and eye shields. It generates most of its revenues from the sale of products across the United States.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.